Pfizer's Options: A Look at What the Big Money is Thinking

Comments
Loading...

Whales with a lot of money to spend have taken a noticeably bearish stance on Pfizer.

Looking at options history for Pfizer PFE we detected 12 trades.

If we consider the specifics of each trade, it is accurate to state that 16% of the investors opened trades with bullish expectations and 75% with bearish.

From the overall spotted trades, 3 are puts, for a total amount of $107,286 and 9, calls, for a total amount of $555,074.

Predicted Price Range

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $30.0 for Pfizer during the past quarter.

Analyzing Volume & Open Interest

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.

This data can help you track the liquidity and interest for Pfizer's options for a given strike price.

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Pfizer's whale activity within a strike price range from $15.0 to $30.0 in the last 30 days.

Pfizer Option Volume And Open Interest Over Last 30 Days

Options Call Chart

Biggest Options Spotted:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
PFE CALL SWEEP NEUTRAL 01/31/25 $0.37 $0.34 $0.37 $26.50 $110.2K 17.7K 6.0K
PFE CALL SWEEP BEARISH 02/21/25 $0.35 $0.34 $0.34 $28.00 $85.0K 71.6K 2.5K
PFE CALL SWEEP BULLISH 02/21/25 $0.33 $0.3 $0.33 $28.00 $82.5K 71.6K 2.5K
PFE CALL TRADE BEARISH 05/16/25 $12.1 $12.0 $12.02 $15.00 $60.1K 50 50
PFE CALL TRADE BEARISH 12/19/25 $2.09 $1.98 $1.98 $27.50 $59.4K 5.8K 501

About Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Following our analysis of the options activities associated with Pfizer, we pivot to a closer look at the company's own performance.

Pfizer's Current Market Status

  • With a volume of 15,272,975, the price of PFE is down -0.69% at $26.68.
  • RSI indicators hint that the underlying stock may be approaching overbought.
  • Next earnings are expected to be released in 7 days.

Professional Analyst Ratings for Pfizer

Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $29.0.

Turn $1000 into $1270 in just 20 days?

20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * An analyst from Citigroup has decided to maintain their Neutral rating on Pfizer, which currently sits at a price target of $29. * Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Pfizer, targeting a price of $29.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Pfizer, Benzinga Pro gives you real-time options trades alerts.

Overview Rating:
Speculative
50%
Technicals Analysis
66
0100
Financials Analysis
40
0100
Overview
Market News and Data brought to you by Benzinga APIs
Date of Trade
ticker
Put/Call
Strike Price
DTE
Sentiment

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!